Research analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO – Get Free Report) (TSE:APS) in a report issued on Thursday. The brokerage set a “hold” rating on the biotechnology company’s stock.
Separately, HC Wainwright decreased their target price on Aptose Biosciences from $7.00 to $2.00 and set a “buy” rating on the stock in a research report on Wednesday.
View Our Latest Research Report on Aptose Biosciences
Aptose Biosciences Trading Down 22.1 %
Institutional Investors Weigh In On Aptose Biosciences
A hedge fund recently bought a new stake in Aptose Biosciences stock. Armistice Capital LLC acquired a new stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO – Free Report) (TSE:APS) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,713,000 shares of the biotechnology company’s stock, valued at approximately $1,300,000. Armistice Capital LLC owned 9.46% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by hedge funds and other institutional investors.
About Aptose Biosciences
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Further Reading
- Five stocks we like better than Aptose Biosciences
- Investing In Automotive Stocks
- Tesla Investors Continue to Profit From the Trump Trade
- Learn Technical Analysis Skills to Master the Stock Market
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- What is the S&P 500 and How It is Distinct from Other Indexes
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.